Can Rocket Lab Stock Become the Next SpaceX-Like Success Story?

Rocket Lab (NASDAQ:RKLB) is doing thing uncommon successful aerospace. It is gathering a afloat vertically integrated abstraction level portion inactive burning cash. Q1 gross deed $200.35 million, up 63.5% twelvemonth implicit year, backlog reached $2.20 billion, and absorption conscionable announced an $8 cardinal acquisition of Iridium Communications.

Shares are up 33.44% twelvemonth to day to $93.09. Can this banal deed $175 successful 2027 and genuinely go the adjacent SpaceX-caliber story? Let's bash the math.

Why Rocket Lab Shares Have Sold Off From May's Peak

The near-term representation is ugly. RKLB is down 5.02% implicit the past week and 15.43% implicit the past month, good disconnected its May peak.

Three things are weighing connected the stock. A $3 cardinal at-the-market equity offering announced June 24 raised dilution fears. A securities people enactment was filed July 1 implicit Neutron timeline disclosures.

And SpaceX's June 12 IPO triggered superior rotation retired of smaller abstraction names. With a beta of 2.553, RKLB amplifies each plaything successful sentiment. Right present that volatility is moving against holders.

Wall Street Sees 22% Upside. I See Room for More.

Consensus people terms sits astatine $114.10, with 3 beardown buys, 11 buys, 4 holds, and zero sells. Bullish sentiment stands astatine 78%. Our basal lawsuit lands astatine $124.25, implying 33.48% upside, with an optimistic script of $156.80 and a carnivore lawsuit astatine $97.12. Confidence is moderate.

Act now: the expert who called NVIDIA successful 2010 conscionable named his apical 10 AI stocks — and Rocket Lab didn't marque the cut. Grab the names FREE today.

I deliberation the sell-side is down the curve. Most targets were struck earlier the Iridium deal, and Roth Capital has already raised to $130. If Neutron flies successful Q4 and Golden Dome contracts commencement converting, the statement volition follow.

The Path to $175 Per Share

Reaching $175 from today's $93.09 requires a summation of 88%. With guardant EPS astatine -$0.34, a $175 terms implies a guardant P/E of -515x, a meaningless fig due to the fact that Rocket Lab remains unprofitable.